Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-03-06 | Joseph M. Patti, Ph.D. (Director) listed as a current director. |
| 2020-10-22 | Joseph M. Patti, Ph.D. has served as a member of the board of directors since the consummation of the Merger. ... Dr. Patti was selected as a director because of his scientific knowledge and background and experience in developing numerous preclinical and clinical bio-pharmaceutical product candidates, as well as his senior management experience over the past decade in developing and implementing the business and financial strategies of emerging, publicly-traded biopharmaceutical companies and serving as a public company director. ... Dr. Patti received fees earned or paid in cash of $30,857 in 2019. ... Dr. Patti received option awards valued at $63,249 in 2019. ... Total compensation for Dr. Patti in 2019 was $94,106. |
| 2021-02-26 | The special committee of the Board comprised of Todd R. Patrick, Joseph M. Patti and Robin C. Kramer, determined that the Purchase Agreement and the transactions contemplated thereby, including the Private Placement, are expedient and in the best interests of the Company and its shareholders. |
| 2021-04-21 | Joseph M. Patti, Ph.D. has served as a member of the Board of Directors since the consummation of the Merger in May 2019. ... Dr. Patti was selected as a director because of his scientific knowledge and background and experience in developing numerous preclinical and clinical bio-pharmaceutical product candidates, as well as his senior management experience over the past decade in developing and implementing the business and financial strategies of emerging, publicly-traded biopharmaceutical companies and serving as a public company director. |
| 2022-03-09 | Joseph M. Patti, Ph.D. (Director)(6) Consists of 38,883 shares of Common Stock that Dr. Patti has the right to acquire from us within 60 days of January 31, 2022, pursuant to the exercise of stock options. |
| 2022-10-17 | Joseph M. Patti, Ph.D. has served as a member of the board of directors since the consummation of the Merger in May 2019. In June 2022, Dr. Patti was appointed President and Chief Executive Officer and director of Evecxia Therapeutics, Inc., and since February 2018, has been the President of JP Biotech Advisors, Inc., which provides strategic growth and drug development advice to emerging biotechnology companies. Dr. Patti was Executive Chairman of AgilVax, Inc. from November 2018 until August 2019, when he was appointed President and Chief Executive Officer and director, until July 2021. From November 2012, Dr. Patti served as Aviragen Therapeutics, Inc.’s Executive Vice President of Corporate Development and Strategy until October 2014, when he was appointed the company’s President and Chief Executive Officer and director. He served in those roles until February 2018, when Aviragen merged with Vaxart, Inc. Prior to joining Aviragen, Dr. Patti co-founded Inhibitex, Inc. in 1994 and served as its Chief Scientific Officer and Senior Vice President of Research and Development from 2007 until it was acquired by Bristol Myers Squibb in February 2012. He also served as its Chief Scientific Officer and Vice President of Research and Development from 2005 to 2007 and as Vice President, Preclinical Development prior to that. Dr. Patti was a director of Inhibitex from 1998 to 2005. Before co-founding Inhibitex, Dr. Patti was an Assistant Professor at Texas A&M’s Institute of Biosciences and Technology and served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. |
| 2023-08-03 | Joseph M. Patti, Ph.D. has served as a member of the board of directors since the consummation of the Merger in May 2019. Since February 2018, he has been the President of JB Biotech Advisors, Inc., which provides strategic growth and drug development advice to emerging biotechnology companies. |
| 2024-04-29 | Joseph M. Patti, Ph.D. has served as a member of the board of directors since the consummation of the Merger in May 2019. Since February 2018, he has been the President of JB Biotech Advisors, Inc., which provides strategic growth and drug development advice to emerging biotechnology companies. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-10-03 | Joseph M. Patti, Ph.D., age 50, joined the Company on November 12, 2012 and served as its Executive Vice President of Corporate Development and Strategy until October 1, 2014, when he was appointed as the Company’s President and Chief Executive Officer. |
| 2015-09-30 | Joseph M. Patti, Ph.D., age 51, joined the Company in November 2012 and served as its Executive Vice President of Corporate Development and Strategy until October 1, 2014, when he was appointed as the Company’s President and Chief Executive Officer and a director. |
| 2016-09-27 | Joseph M. Patti, Ph.D., age 52, joined the Company in November 2012 and served as its Executive Vice President of Corporate Development and Strategy until October 1, 2014, when he was appointed as the Company’s President and Chief Executive Officer and a director. ... Dr. Patti’s scientific knowledge and background and experience in developing numerous preclinical and clinical bio-pharmaceutical product candidates, as well as his senior management experience over the past decade in developing and implementing the business and financial strategies of emerging, publicly-traded biopharmaceutical companies, led to the conclusion that he should serve on the Company’s Board of Directors. |
Data sourced from SEC filings. Last updated: 2026-02-03